ELVN

Enliven Therapeutics Inc

Add to Watchlist

Advanced Chart

18.840

-0.38(-1.977%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

20.260

Open

19.070

VWAP

18.80

Vol

436.28K

Mkt Cap

1.08B

Low

18.435

Amount

8.20M

EV/EBITDA(TTM)

Total Shares

47.04M

814.32M

EV/OCF(TTM)

P/S(TTM)

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. Its second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. ELVN-002 is designed to inhibit wild type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities.

8 Analyst Rating

123.67% Upside

Wall Street analysts forecast ELVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELVN is 42.14 USD with a low forecast of 35.00 USD and a high forecast of 52.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

0 Hold

0 Sell

Strong Buy

123.67% Upside

Current: 18.840

Low

35.00

Averages

42.14

High

52.00

123.67% Upside

Current: 18.840

Low

35.00

Averages

42.14

High

52.00

H.C. Wainwright

NULL -> Buy

maintain

$40 -> $48

2025-07-02

Reason

H.C. Wainwright

Price Target

$40 -> $48

2025-07-02

maintain

NULL -> Buy

Reason

H.C. Wainwright raised the firm's price target on Enliven to $48 from $40 and keeps a Buy rating on the shares after the company presented updated results from the Phase 1a/1b ENABLE trial at EHA 2025. Following the presentation at the medical meeting, the firm contends that ELVN-001 could become "the go-to agent" in chronic myelogenous leukemia.

Goldman Sachs

Salveen Richter

NULL -> Buy

upgrade

$37

2025-06-17

Reason

Goldman Sachs

Salveen Richter

Price Target

$37

2025-06-17

upgrade

NULL -> Buy

Reason

Goldman Sachs analyst Salveen Richter assigned of Enliven with a Buy rating and $37 price target from a previous Early-Stage Biotech designation. The firm cites the company's continued positive Phase 1 data and the announcement of a planned Phase 3 initiation in 2026 for tyrosine kinase inhibitor ELVN-001 in chronic myeloid leukemia for the Buy rating. ELVN-001 remains well-tolerated, with no increased cardiovascular toxicity, and the data supports the potential for once daily dosing without the need for fasting and low drug-drug interactions, the analyst tells investors in a research note.

Baird

Colleen Kusy

Outperform

maintain

$40 -> $52

2025-06-17

Reason

Baird

Colleen Kusy

Price Target

$40 -> $52

2025-06-17

maintain

Outperform

Reason

Baird analyst Colleen Kusy raised the firm's price target on Enliven to $52 from $40 and keeps an Outperform rating on the shares. The firm updated its model as its ELVN-001 data continues to show improvement which supports its compelling profile.

JonesResearch

Soumit Roy

Buy

downgrade

$36 -> $27

2025-05-16

Reason

JonesResearch

Soumit Roy

Price Target

$36 -> $27

2025-05-16

downgrade

Buy

Reason

JonesResearch analyst Soumit Roy lowered the firm's price target on Enliven to $27 from $36 and keeps a Buy rating on the shares. The company's abstract from the Phase 1 late line chronic myeloid leukemia trial with ELVN-001 "was met with a lukewarm initial stock reaction that weakened over time," the analyst tells investors in a research note. The firm says that even though ELVN-001 showed efficacy and safety profile inline with the September 2024 update with two-times the patient population, the market treated the stock with a sell on news approach. Jones sees ELVN-001 performing at least inline with Novartis' Scemblix.

H.C. Wainwright

Buy

maintain

$39 -> $40

2025-05-15

Reason

H.C. Wainwright

Price Target

$39 -> $40

2025-05-15

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Enliven to $40 from $39 and keeps a Buy rating on the shares following the Q1 report.

HC Wainwright & Co.

Robert Burns

Strong Buy

Maintains

$37 → $39

2025-03-21

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$37 → $39

2025-03-21

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Enliven Therapeutics Inc (ELVN.O) is -8.82, compared to its 5-year average forward P/E of -8.99. For a more detailed relative valuation and DCF analysis to assess Enliven Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-8.99

Current PE

-8.82

Overvalued PE

-6.89

Undervalued PE

-11.09

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.59

Current EV/EBITDA

-5.40

Overvalued EV/EBITDA

-2.03

Undervalued EV/EBITDA

-7.14

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

81746.07

Current PS

155617.93

Overvalued PS

185449.21

Undervalued PS

-21957.08